RedHill Biopharma received approval for phase 2/3 COVID-19 study in Russia
On Jul. 16, 2020, RedHill Biopharma announced approval from the Ministry of Health of the Russian Federation for…
-
-
BioAegis received approval to proceed with phase 2 trial of its gelsolin COVID-19 treatment
On Jul. 15, 2020, BioAegis Therapeutics announced that it received regulatory clearance from The Spanish Agency for Medicines…
-
Rigel announces investigator-sponsored trial of fostamatinib in patients with COVID-19 pneumonia
On Jul. 14, 2020, Rigel Pharmaceuticals announced the initiation of an investigator-sponsored tria being conducted by Imperial College…
-
Pneumonia vaccine price dropped dramatically for lower-income countries thanks to the Gavi pneumococcal Advance Market Commitment
On Jun. 16, 2020, lower-income countries across the world have access life-saving pneumococcal conjugate vaccines, which protect against…
-
RedHill Biopharma submited COVID-19 clinical trial application for phase 2/3 study with Opaganib in Russia
On Jun. 10, 2020, RedHill Biopharma announced it had submitted a Clinical Trial Application (CTA) with the Ministry…
-
OpGen released preliminary data demonstrating Unyvero HPN panel for pneumonia identified life-threatening bacterial co-infections in COVID-19 patients
On Jun. 9, 2020, OpGen announced preliminary data from an investigator initiated collaboration with Karolinska Institutet, Stockholm, Sweden,…
-
The FDA approved antibiotic to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
On Jun. 4, 2020, the FDA approved Merck’s Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired…
-
Roche initiated initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
On Jun. 4, 2020, Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA)…
-
Gilead announced results from phase 3 trial of Remdesivir in patients with moderate COVID-19
On Jun. 1, 2020, Gilead Sciences announced topline results from the Phase 3 SIMPLE trial in hospitalized patients…
-
Roche initiated phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
On May 28, 2020, Roche announced it had initiated of a global phase III, randomised, double-blind, multicentre study…
-
Investigational ChAdOx1 nCoV-19 vaccine protects monkeys against COVID-19 pneumonia
On May 16, 2020, a single dose of ChAdOx1 nCoV-19, an investigational vaccine against SARS-CoV-2, has protected six…
-
RedHill Biopharma received FDA approval for COVID-19 clinical study with opaganib in the U.S.
On May 8, 2020, RedHill Biopharma announced the U.S. Food and Drug Administration (FDA) had approved its Investigational…
-
Biotechnology | COVID-19 | FDA | Therapeutics
Mateon announced filing of IND with FDA to evaluate antisense drug candidate OT-101 in COVID-19 patients
On Apr. 27, 2020, Mateon Therapeutics announced announced it has submitted an Investigational New Drug application to the…
-
BioAegis demonstrated Gelsolin therapy can quell the cytokine storm and promote tissue repair
On Apr. 27, 2020, BioAegis Therapeutics announced it had published gene expression data in animal studies where recombinant…
-
OpGen subsidiary Curetis GmbH and Karolinska Institutet collaborated in study of bacterial Co-infections in COVID-19 pneumonia patients
On Apr. 21, 2020, OpGen announced the start of an investigator initiated collaboration with Karolinska Institutet, Sweden, to…
-
RedHill Biopharma announced agreement with NIAID to evaluate RHB-107 against COVID-19
On Apr. 20, 2020, RedHill Biopharma announced an agreement with the National Institute of Allergy and Infectious Diseases…
-
Alexion announced plans to initiate phase 3 study of ULTOMIRISﾮ (ravulizumab-cwvz) in hospitalized patients with severe COVID-19
On Apr. 20, 2020, Alexion announced plans to initiate a global Phase 3 study to investigate ULTOMIRISﾮ (ravulizumab-cwvz)…
-
Chugai started phase III clinical trial of Actemra for COVID-19 pneumonia in Japan
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
-
Mateon achieved milestone in development of OT-101, a phase 3 clinical drug candidate, against COVID-19
On Apr. 6, 2020, Mateon Therapeutics announced that it has delivered the requisite testing results to Golden Mountain…
-
Novartis announced plan to initiate clinical study of Jakavi in severe COVID-19 patients and establish international compassionate use program
On Apr. 2, 2020, Novartis announced plans to initiate a phase III clinical trial in collaboration with Incyte…
-
BioAegis accelerated multiple clinical trial submissions for severe COVID-19 pneumonia patients
On Apr. 2, 2020, BioAegis Therapeutics announced that it was preparing to evaluate plasma gelsolin replacement in severe…
-
Cumberland Pharma Announced Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
On Mar. 23, 2020, Cumberland Pharmaceuticals announced a national initiative to support the treatment of patients with hospital-acquired and…
-
New study expanded understanding of influenza-associated complications
On Mar. 20, 2020, a study was published in JAMA that expands the understanding of influenza-associated complications. Influenza…
-
Roche initiated phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
On Mar. 19, 2020, Roche announced it was working with the U.S. Food & Drug Administration (FDA) to…
-
Israel weighed “compassionate use” of Pluristem therapy for COVID-19
On Mar. 17, 2020, Israel’s Health Ministry announced that it had approved a request by Pluristem Therapeutics to…
-
MediciNova announced plans to develop MN-166 (ibudilast) for severe pneumonia and ARDS
On Mar. 9, 2020, MediciNova announced that it planned to initiate development of MN-166 (ibudilast) for severe pneumonia…
-
COVID-19 coronavirus spike holds infectivity details
On Feb. 24, 2020, researchers reported that the spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia…
-
NIH officials discussed novel coronavirus that recently emerged in China
On Jan. 23, 2020, the new cluster of viral pneumonia cases originating in Wuhan, China, marked the third…
-
COVID-19 | Diagnostics | WHO
Novel coronavirus identified as cause of a cluster of pneumonia cases in Wuhan, China
On Jan. 9, 2020, the World Health Organization announced that a novel coronavirus had been identified as the…
-
Cases of pneumonia detected in Wuhan, China were first reported to the WHO
On Dec. 31, 2019, the World Health Organization (WHO) declared the Coronavirus outbreak a global pandemic. To date,…
